Talk:Preimplantation Genetic Screening: Difference between revisions
(Created page with "{{Talk Page}} ==2011== ===Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?=== J Assist Reprod Genet. 2011 Sep;28(...") |
(→2011) |
||
| Line 2: | Line 2: | ||
==2011== | ==2011== | ||
===The genetic screening of preimplantation embryos by comparative genomic hybridisation=== | |||
Reprod Biol. 2011 Dec;11 Suppl 3:51-60. | |||
Traversa MV, Marshall J, McArthur S, Leigh D. | |||
Source | |||
Genea, Level 2, 321 Kent Street, Sydney NSW 2000, Australia; e-mail: maria.traversa@genea.com.au. | |||
Abstract | |||
Comparative genomic hybridization (CGH) is an indirect DNA-based test which allows for the accurate analysis of aneuploidy involving any of the 24 types of chromosomes present (22 autosomes and the X and Y sex chromosomes). Traditionally, embryos have been screened using fluorescence in situ hybridization (FISH) - a technique that was limited in the number of chromosomes able to be identified in any one sample. Early CGH reports on aneuploidy in preimplantation embryos showed that any of the 24 chromosomes could be involved and so FISH methods were going to be ineffective in screening out abnormal embryos. Our results from routine clinical application of array CGH in preimplantation genetic diagnosis (PGD) patients confirm previous reports on patterns of chromosomal contribution to aneuploidy. The pregnancy outcomes following embryo transfer also indicate that despite the requirement to freeze embryos, rates are encouraging, and successful ongoing pregnancies can be achieved. | |||
PMID 22200879 | |||
===Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?=== | ===Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?=== | ||
Revision as of 12:37, 16 January 2012
| About Discussion Pages |
|---|
Glossary Links
Cite this page: Hill, M.A. (2024, June 23) Embryology Preimplantation Genetic Screening. Retrieved from https://embryology.med.unsw.edu.au/embryology/index.php/Talk:Preimplantation_Genetic_Screening |
2011
The genetic screening of preimplantation embryos by comparative genomic hybridisation
Reprod Biol. 2011 Dec;11 Suppl 3:51-60.
Traversa MV, Marshall J, McArthur S, Leigh D. Source Genea, Level 2, 321 Kent Street, Sydney NSW 2000, Australia; e-mail: maria.traversa@genea.com.au.
Abstract
Comparative genomic hybridization (CGH) is an indirect DNA-based test which allows for the accurate analysis of aneuploidy involving any of the 24 types of chromosomes present (22 autosomes and the X and Y sex chromosomes). Traditionally, embryos have been screened using fluorescence in situ hybridization (FISH) - a technique that was limited in the number of chromosomes able to be identified in any one sample. Early CGH reports on aneuploidy in preimplantation embryos showed that any of the 24 chromosomes could be involved and so FISH methods were going to be ineffective in screening out abnormal embryos. Our results from routine clinical application of array CGH in preimplantation genetic diagnosis (PGD) patients confirm previous reports on patterns of chromosomal contribution to aneuploidy. The pregnancy outcomes following embryo transfer also indicate that despite the requirement to freeze embryos, rates are encouraging, and successful ongoing pregnancies can be achieved.
PMID 22200879
Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?
J Assist Reprod Genet. 2011 Sep;28(9):833-49. Epub 2011 Jul 9.
Ly KD, Agarwal A, Nagy ZP. Source Center for Reproductive Medicine, Cleveland Clinic, Cleveland, Ohio, USA. kimdaoly@yahoo.com
Abstract
Despite an ongoing debate over its efficacy, preimplantation genetic screening (PGS) is increasingly being used to detect numerical chromosomal abnormalities in embryos to improve implantation rates after IVF. The main indications for the use of PGS in IVF treatments include advanced maternal age, repeated implantation failure, and recurrent pregnancy loss. The success of PGS is highly dependent on technical competence, embryo culture quality, and the presence of mosaicism in preimplantation embryos. Today, cleavage stage biopsy is the most commonly used method for screening preimplantation embryos for aneuploidy. However, blastocyst biopsy is rapidly becoming the more preferred method due to a decreased likelihood of mosaicism and an increase in the amount of DNA available for testing. Instead of using 9 to 12 chromosome FISH, a 24 chromosome detection by aCGH or SNP microarray will be used. Thus, it is advised that before attempting to perform PGS and expecting any benefit, extended embryo culture towards day 5/6 should be established and proven and the clinical staff should demonstrate competence with routine competency assessments. A properly designed randomized control trial is needed to test the potential benefits of these new developments.
PMID 21743973
